Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL297718 | 0.98 | TDP1 (0.79) | TDP1LMNAMAPK1HIF1ASLC6A2 | |
| SCHEMBL297349 | 0.98 | TDP1 (0.79) | TDP1LMNAMAPK1HIF1ASLC6A2 | |
| SCHEMBL8772606 | 0.98 | TDP1 (0.79) | TDP1LMNAMAPK1HIF1ASLC6A2 | |
| SCHEMBL9189899 | 0.94 | TDP1 (0.85) | TDP1LMNAMAPK1HIF1ASLC6A2 | |
| SCHEMBL296938 | 0.94 | TDP1 (0.78) | TDP1LMNAMAPK1HIF1ASLC6A2 | |
| SCHEMBL223441 | 0.90 | TDP1 (1.00) | TDP1LMNAMAPK1HIF1ASLC6A2 | |
| SCHEMBL17466182 | 0.88 | TDP1 (0.96) | TDP1LMNAMAPK1HIF1ASLC6A2 | |
| SCHEMBL2069111 | 0.88 | TDP1 (0.96) | TDP1LMNAMAPK1HIF1ASLC6A2 | |
| SCHEMBL11896606 | 0.88 | TDP1 (0.96) | TDP1LMNAMAPK1HIF1ASLC6A2 | |
| SCHEMBL223238 | 0.88 | TDP1 (0.96) | TDP1LMNAMAPK1HIF1ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115626-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION OF ISOTHIOCYANATES | CHURCH & DWIGHT CO., INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-11801273-B2 | Compositions and methods to increase production of isothiocyanates | CHURCH & DWIGHT CO., INC. (US) | 2023-10-31 | — | — | US | disclosed |
| WO-2023133494-A2 | OIL-BASED ISOTHIOCYANATE PRODUCTS AND PROCESSES FOR PREPARING OIL-BASED ISOTHIOCYANATE PRODUCTS | BRASSICA PROTECTION PRODUCTS LLC (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2022140409-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION OF ISOTHIOCYANATES | CHURCH & DWIGHT CO., INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20220193152-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION OF ISOTHIOCYANATES | CHURCH & DWIGHT CO., INC. (US) | 2022-06-23 | — | — | US | disclosed |
| US-20200087338-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK PHARMACEUTICALS INC (US) | 2020-03-19 | — | — | US | disclosed |
| EP-3553072-A1 | COMPOSITIONS COMPRISING DINUCLEOTIDE PRODRUGS | Spring Bank Pharmaceuticals, Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10376533-B2 | Compositions and methods for treating viral infections | SPRING BANK PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-10344046-B2 | Nucleotide and oligonucleotide prodrugs | SPRING BANK PHARMACEUTICALS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| EP-3090748-B1 | COMPOSITIONS COMPRISING NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK PHARMACEUTICALS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-5071443-A | BLUE AZO DYESTUFF MIXTURE FOR STRONG BLUE COLOR ON HYDROPHOBIC FIBERS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1991-12-10 | — | — | US | disclosed |
| EP-0420806-A1 | Phosphonic acids, process for preparation and use as an active pharmaceutical composition | CIBA-GEIGY AG (CH) | 1991-04-03 | — | — | EP | disclosed |
| EP-0391121-A1 | Monoazo dyes, their preparation and use | CASSELLA Aktiengesellschaft (DE) | 1990-10-10 | — | — | EP | disclosed |
| EP-0387642-A2 | Mixture of dyes | CASSELLA Aktiengesellschaft (DE) | 1990-09-19 | — | — | EP | disclosed |
| US-4678476-A | HIGH TINCTORIAL STRENGTH, COLORFASTNESS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1987-07-07 | — | — | US | disclosed |
| EP-0222255-A2 | Mixtures of blue disperse dyes and their use in dyeing polyesters | CASSELLA Aktiengesellschaft (DE) | 1987-05-20 | — | — | EP | disclosed |
| US-4487772-A | CARDIOTONIC AGENTS | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| US-4468402-A | Carbostyril derivatives, process for producing the same and cardiotonic compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-28 | — | — | US | disclosed |
| US-4454130-A | CARDIOTONIC, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
| US-4435404-A | ANTICOAGULANTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087338-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | TYMP, PNP, DUT | TDP1 593/4885LMNA 1746/4885MAPK1 3112/4885 |
| US-10376533-B2 | Compositions and methods for treating viral infections | SLC10A1, HAVCR2, CYP3A43 | TDP1 2064/4885LMNA 2008/4885MAPK1 3157/4885 |
| US-10344046-B2 | Nucleotide and oligonucleotide prodrugs | TYMP, PNP, DUT | TDP1 593/4885LMNA 1746/4885MAPK1 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.